Uncategorized

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the company’s second hearing restoration candidate for sensorineural hearing loss (SNHL). FX-345 is a combination of two small

The 3rd Digital EUHA Spring  Conference will kick off on March 31, 2023. The successful concept is an  important date for further training that is firmly anchored in the calendars of  hearing aid acousticians. The organization expects numerous international participants this year. For the first time, the event has an international focus and will also be offered in English.   Lectures

TÜBINGEN, GERMANY — Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical development, with a particular focus on its use as an etiology-agnostic otoprotectant for patients with acute forms of sensorineural hearing

EDEN PRAIRIE, MINNESOTA – Starkey Chief Technology Officer and Executive Vice President of Engineering, Achin Bhowmik, Ph.D., has been named a 2022 Notable Leader in Health Care by Twin Cities Business Magazine. This award honors Minnesota leaders who are boldly advancing the health care industry through technology and innovation.   “I want to congratulate Achin on this well-deserved recognition. The vision to reinvent the

Next year, the Digital EUHA Spring Conference will kick off on 31 March 2023. The successful training format is an important date firmly anchored in the calendars of both EUHA members and non-members. The organization is also expecting numerous international participants.  Lectures and live chats with the speakers will be offered in digital format on the day of the event,

WASHINGTON, D.C. – U.S. Senators Rob Portman (R-OH) and Maggie Hassan (D-NH) applauded the House passage of their Early Hearing Detection and Intervention Act of 2022, legislation that will reauthorize current research and improve public health programs for early detection, diagnosis, and treatment of hearing loss in newborns, infants, and young children for five additional years. Senator Portman led the effort to

PISCATAWAY, NEW JERSEY – Reaffirming its commitment to supporting veterans and active military members, Signia announced today it will match up to $25,000 in donations on December 30, 2022, to benefit Fisher House Foundation. If the goal is reached, the foundation will receive a total of $50,000 to aid its mission of building homes near military and VA medical facilities

STAFA, SWITZERLAND – Sonova Holding AG announced that it has successfully completed the acquisition of the HYSOUND Group, first announced on August 19, 2022. As one of the leading nationwide chains of audiological care clinics in China, with around 200 clinics in over 20 provinces and more than 70 cities, the HYSOUND Group will significantly enlarge Sonova’s store footprint and

MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to OTOF-GT, Sensorion’s lead gene therapy program, intended for the treatment of otoferlin gene mediated hearing loss.

LYNGE, DENMARK – WS Audiology today announced a solid performance for the fiscal year 2021/22, which ended on September 30, 2022, reporting revenue and earnings growth in line with expectations. WSA Highlights Full Year 2021/22 Highlights Q4 2021/22 “Following a strong first half, the second half of the year was impacted by general macro weakness. Still, we delivered a solid performance